The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and manageable toxicity of mogamulizumab in a real-world North American cohort of adult T-cell leukemia/lymphoma (ATLL).
 
Emma Cordover
No Relationships to Disclose
 
Kith Pradhan
No Relationships to Disclose
 
Latoya Townsend
No Relationships to Disclose
 
Mendel Goldfinger
No Relationships to Disclose
 
Ioannis Mantzaris
Honoraria - Syndax
Travel, Accommodations, Expenses - Adaptive Biotechnologies
 
Nishi Shah
No Relationships to Disclose
 
Aditi Shastri
Honoraria - Great Debates and Updates; Peerview
Consulting or Advisory Role - Kymera; Ryvu Therapeutics
Research Funding - Kymera; Ryvu Therapeutics
 
Noah Kornblum
No Relationships to Disclose
 
Dennis Cooper
No Relationships to Disclose
 
Ridhi Gupta
No Relationships to Disclose
 
Lauren Shapiro
No Relationships to Disclose
 
Kira Gritsman
No Relationships to Disclose
 
Marina Konopleva
No Relationships to Disclose
 
Beth McLellan
No Relationships to Disclose
 
B. Hilda Ye
Stock and Other Ownership Interests - Humana; United Health Group
Research Funding - RAPT Therapeutics
 
Alyssa De Castro
No Relationships to Disclose
 
Roy Browne
No Relationships to Disclose
 
Salvatore Lia
No Relationships to Disclose
 
Amit Verma
Leadership - Cardiff Oncology (I); CytomX Therapeutics (I)
Stock and Other Ownership Interests - Roshon Therapeutics; Stelexis Therapeutics; ThromboGenics
Honoraria - Stelexis Therapeutics
Consulting or Advisory Role - Janssen; Keros Therapeutics; Ryvu Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Prelude Therapeutics; Ryvu Therapeutics
 
Alejandro Sica
No Relationships to Disclose